Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery.

@article{Bertagna2013ApproachTT,
  title={Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery.},
  author={Xavier Y. Bertagna and Laurence Guignat},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2013},
  volume={98 4},
  pages={
          1307-18
        }
}
  • X. Bertagna, L. Guignat
  • Published 2 July 2013
  • Medicine, Biology
  • The Journal of clinical endocrinology and metabolism
Although it is the ideal treatment, pituitary surgery is not always successful, and success is not always lasting. Close surveillance, clinical and biological, will detect immediate failure or late recurrence. The reason must be thoroughly explored with the somewhat dogmatic rule that the patient should be offered the best surgery in expert hands, and a repeat surgical attempt must be systematically discussed. When repeat pituitary surgery is not indicated or has failed, then comes the… 

Figures and Tables from this paper

Update on Hypercortisolism Therapy.
TLDR
Pituitary radiotherapy represents a second-line treatment in patients not cured with surgery, or when medical treatment is not suitable/efficacious, although the rate of cure is largely variable and achieved only in the long term, and is associated with the risk of developing secondary hypopituitarism.
Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery
TLDR
There is currently no ideal single treatment option that provides high and rapid efficacy, low adverse effects, and preserves normal pituitary-adrenal axis function for persistent/recurrent Cushing’s disease.
Recent advances in the medical treatment of Cushing’s disease
TLDR
This commentary will focus on recent advances in the medical treatment of Cushing’s, with a focus on newly approved ACTH modulators and glucocorticoid receptor blockers.
Therapeutic strategies for Cushing’s syndrome: an update
TLDR
This review summarizes the different medical approaches for treating Cushing’s syndrome (adrenal- or pituitary-directed drugs, glucocorticoid receptor antagonist, alone or in combination); mifepristone, recently approved for use in controlling hyperglycemia secondary to hypercortisolism.
Medical management of Cushing’s disease
TLDR
It is likely that novel, targeted medical therapies will be developed to treat CD, as the pathogenesis of CD becomes better understood at the molecular level, and the long term efficacy and safety of medical therapies for hypercortisolism need to be evaluated.
Current approaches to the pharmacological management of Cushing's disease
  • M. Molitch
  • Medicine, Biology
    Molecular and Cellular Endocrinology
  • 2015
Recurrence of Cushing ’ s disease after bilateral adrenalectomy : A myth or reality ?
TLDR
The importance of long-term patient monitoring after total bilateral adrenalectomy and individual dosing of replacement therapy is highlighted, as a case of a patient with an atypical corticotropinoma/carcinoma and CD recurrence after bilateral Adrenalectomy is presented.
Persistent Cushing's Disease after Transsphenoidal Surgery: Challenges and Solutions.
  • A. Albani, M. Theodoropoulou
  • Medicine
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2020
TLDR
The factors that could predict remission or persistence of Cushing's disease after pituitary surgery are analyzed and the therapeutic options in case of surgical failure are revised.
The Treatment of Cushing's Disease.
TLDR
Recent experience suggests that the combination of different drugs may be able to control cortisol excess in a great majority of patients with Cushing's syndrome.
Detection of recurrent Cushing’s disease: proposal for standardized patient monitoring following transsphenoidal surgery
TLDR
This follow-up algorithm aims to enable early diagnosis and treatment of recurrent CD, thereby minimizing the detrimental effects of hypercortisolism, and begin addressing the need for standardized guidelines for vigilant monitoring of CD patients treated by TSS, as demonstrated by the reported rates of recurrence.
...
...

References

SHOWING 1-10 OF 57 REFERENCES
Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease.
TLDR
Magnetic resonance imaging was not usually helpful in determining therapeutic strategies; however, inferior petrosal sinus sampling was critical in providing confidence that the disease was of pituitary origin.
Early repeat surgery for persistent Cushing's disease.
TLDR
Early reoperation induced immediate remission of hypercortisolism in 71% of cases, but did so at the expense of a high risk of hypopituitarism, since the alternative treatments also have potential adverse effects.
Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery.
TLDR
Recurrent and persistent CD consistently results from residual tumor, and occult dural invasion by tumor may also underlie recurrences of other types of pituitary adenomas.
Metyrapone in long-term management of Cushing's disease.
TLDR
Routine use of metyrapone is recommended as an adjunct to more definitive treatment in all patients who present with Cushing's syndrome, irrespective of aetiology.
Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.
TLDR
Ketoconazole is a safe and efficacious treatment in CD, particularly in patients for whom surgery is contraindicated, or delayed because of the absence of image of adenoma on magnetic resonance imaging.
Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery.
TLDR
A positive response to vasopressin analogs and/or CRH tests occurs early in recurrence, followed by an increase in midnight cortisol, while UC elevation is at a later stage.
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
TLDR
Pasireotide produced a decrease in UFC levels in 76% of patients with Cushing's disease during the treatment period of 15 d, with direct effects on ACTH release, suggesting that pasireotide holds promise as an effective medical treatment for this disorder.
Surgical Treatment of Recurrent Cushing's Disease
TLDR
By performing repeated selective adenomectomy, patients with recurrent Cushing's disease can be cured without the risk of endocrine deficits or major complications.
Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma.
TLDR
Repeated transsphenoidal surgery is a more effective treatment for recurrent or residual mass than it is for hormone hypersecretion and has acceptable rates of morbidity and mortality.
Sustained remission of Cushing's disease with mitotane and pituitary irradiation.
TLDR
Low doses of mitotane were given orally to 36 patients with Cushing's disease, concurrently with or after pituitary cobalt irradiation, and initial remission was due mainly to the adrenal effect of Mitotane.
...
...